DOCSLIB.ORG

Supplementary File 1: Search Strategy Search Strategy for MEDLINE 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary File 1: Search Strategy Search Strategy for MEDLINE 1 Supplementary file 1: Search strategy Search strategy for MEDLINE 1. depressive disorder"[MeSH Terms] 2. depressive 3. 1 OR 2 4. disorder 5. depressive disorder 6. depression 7. depression"[MeSH Terms] 8. depressive 9. 4 OR 5 OR 6 OR 7 OR 8 10. mace 11. macce 12. "major adverse cardiac event" 13. "major adverse cardiac events" 14. "Major Adverse Cardiac and Cerebrovascular event" 15. "Major Adverse Cardiac and Cerebrovascular events" 16. “cardiac death” 17. ("myocardial infarction"[MeSH Terms] OR ("myocardial" AND "infarction") OR "myocardial infarction") 18. revascularization 19. ("stroke"[MeSH Terms] OR "stroke") 20. ("mortality"[Subheading] OR "mortality" OR "mortality"[MeSH Terms]) 21. 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 22. ("serotonin uptake inhibitors" OR "serotonin uptake inhibitors"[MeSH Terms] 23. ("serotonin" AND "uptake" AND "inhibitors") 24. "serotonin uptake inhibitors" 25. "ssri" 26. (Selective AND ("serotonin"[MeSH Terms] OR "serotonin") AND re-uptake AND ("antagonists and inhibitors"[Subheading] OR ("antagonists" AND "inhibitors") OR "antagonists and inhibitors" OR "inhibitors")) 27. (serotonin-specific AND reuptake AND ("antagonists and inhibitors” OR ("antagonists" AND "inhibitors"[Subheading]) OR "antagonists and inhibitors" OR "inhibitors")) 28. "citalopram"[MeSH Terms] OR "citalopram" 29. "fluoxetine"[MeSH Terms] OR "fluoxetine" 30. "paroxetine"[MeSH Terms] OR "paroxetine" 31. "sertraline"[MeSH Terms] OR "sertraline" 32. "alaproclate"[Supplementary Concept] OR "alaproclate” 33. "fluvoxamine"[MeSH Terms] OR "fluvoxamine" 34. "etoperidone"[Supplementary Concept] OR "etoperidone" 35. "citalopram"[MeSH Terms] OR "citalopram" OR "escitalopram" 36. "zimeldine"[MeSH Terms] OR "zimeldine" OR "zimelidine" 37. 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 38. randomized controlled trial[pt] 39. controlled clinical trial[pt] 40. randomized[tiab] 41. placebo[tiab] 42. clinical trials as topic[mesh:noexp] 43. randomly[tiab] 44. trial[ti] 45. (animals[mh] NOT humans [mh]) 46. 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44 NOT 45 47 21 AND 37 AND 46 48. "humans"[MeSH Terms] 49. 47 AND 48 50. English[lang] 51. 49 AND 50 Date of Search: 01/31/2017 Results: 234 articles found Search strategy for EMBASE 1. 'depression'/exp 2. depression 3. depressive 4. 1 OR 2 OR 3 OR 5. 'mace'/exp 6. mace 7. mace 8. 'major adverse cardiac event'/exp 9. 'major adverse cardiac event' 10. 'major adverse cardiac events' 11. 'major adverse cardiac and cerebrovascular event'/exp 12. 'major adverse cardiac and cerebrovascular event' 13. 'major adverse cardiac and cerebrovascular events' 14. 'cardiac death'/exp 15. OR 'cardiac death' 16. 'mortality'/exp 17. mortality 18. 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 19. 'ssri'/exp 20. ssri 21. selective 22. 'serotonin'/exp OR serotonin 23. 're uptake' 24. 'inhibitors'/exp OR inhibitors 25. 'serotonin specific' 26. reuptake 27. 'inhibitors'/exp OR inhibitors 28. 'citalopram'/exp 29. citalopram 30. 'fluoxetine'/exp 31. fluoxetine 32. 'paroxetine'/exp 33. paroxetine 34. 'sertraline'/exp 35. sertraline 36. 'alaproclate'/exp 37. alaproclate 38. 'fluvoxamine'/exp 39. fluvoxamine 40. 'etoperidone'/exp 41. etoperidone 42. 'escitalopram'/exp 43. escitalopram 44. 'zimelidine'/exp 45. zimelidine 46. 19 OR 20 OR 21 AND 22 AND 23 AND 24 OR 25 AND 26 AND 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45 47 'crossover procedure':de 48. 'double-blind procedure':de 49. 'randomized controlled trial':de 50. 'single-blind procedure':de 51. random*:de,ab,ti 52. factorial*:de,ab,ti 53. crossover*:de,ab,ti 54. (cross NEXT/1 over*): de,ab,ti 55. placebo*:de,ab,ti 56. (doubl* NEAR/1 blind*):de,ab,ti 57. (singl* NEAR/1 blind*):de,ab,ti 58. assign*:de,ab,ti 59. allocat*:de,ab,ti 60. volunteer*:de,ab,ti) 61. [english]/lim 62. 47 OR 48 OR 49 OR 50 OR 51 OR 52 OR 53 OR 54 OR 55 OR 56 OR 57 OR 58 OR 59 OR 60 OR 61 63. 18 AND 46 AND 62 Date of Search: 01/31/2017 Results: 828 articles found Search strategy for Cochrane 1. depression 2. depressive 3. 1 OR 2 4. mace 5. mace 6. "major adverse cardiac event" 7. "major adverse cardiac events" 8. "Major Adverse Cardiac and Cerebrovascular event" 9. "Major Adverse Cardiac and Cerebrovascular events" 10. "cardiac death" 11. mortality 12. 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 13. SSRI 14. Selective serotonin re-uptake inhibitors 15. serotonin-specific reuptake inhibitors 16. Citalopram 17. Fluoxetine 18. Paroxetine 19. Sertraline 20. Alaproclate 21. Fluvoxamine 22. Etoperidone 23. Escitalopram 24. Zimelidine 25. 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 26. 3 AND 12 AND 25 Date of Search: 01/31/2017 Results: 8 articles found .
Load more

Recommended publications
  • Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease
    International Journal of Molecular Sciences Review Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease Michiel Van Bulck 1,2 , Ana Sierra-Magro 1,2, Jesus Alarcon-Gil 1, Ana Perez-Castillo 1,2 and Jose A. Morales-Garcia 1,2,3,* 1 Instituto de Investigaciones Biomédicas (CSIC-UAM), Arturo Duperier, 4. 28029 Madrid, Spain; [email protected] (M.V.B.); [email protected] (A.S.-M.); [email protected] (J.A.-G.); [email protected] (A.P.-C.) 2 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Valderrebollo, 5, 28031 Madrid, Spain 3 Departamento de Biología Celular, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Plaza Ramón y Cajal s/n, 28040 Madrid, Spain * Correspondence: [email protected] Received: 31 December 2018; Accepted: 3 February 2019; Published: 8 February 2019 Abstract: Neurodegenerative disorders affect around one billion people worldwide. They can arise from a combination of genomic, epigenomic, metabolic, and environmental factors. Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer’s and Parkinson’s diseases. A progressive neurodegenerative process and neuroinflammation occur, and no current therapies can prevent, slow, or halt disease progression. To date, no novel disease-modifying therapies have been shown to provide significant benefit for patients who suffer from these devastating disorders. Therefore, early diagnosis and the discovery of new targets and novel therapies are of upmost importance. Neurodegenerative diseases, like in other age-related disorders, the progression of pathology begins many years before the onset of symptoms. Many efforts in this field have led to the conclusion that exits some similar events among these diseases that can explain why the aging brain is so vulnerable to suffer neurodegenerative diseases.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • In Utero Exposure to Antidepressant Drugs and Risk of Attention Deficit Hyperactivity Disorder (ADHD)
    FACULTY OF HEALTH SCIENCE; AARHUS UNIVERSITY In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder (ADHD): A nationwide Danish cohort study Research year report Kristina Laugesen Department of Clinical Epidemiology, Aarhus University Hospital Supervisors Henrik Toft Sørensen, MD, PhD, DMSc, professor (main supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Morten Olsen, MD, PhD (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Ane Birgitte Telén Andersen, PhD-student, MPH (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Preface This study was carried out during my research year at Department of Clinical Epidemiology, Aarhus University Hospital, Denmark (February 2012 - January 2013). I would like to express my gratefulness to my main supervisor Henrik Toft Sørensen and the Department of Clinical Epidemiology. This department contributes to research of high standard and I feel lucky to have been a part of the research environment here. From my point of view a research environment of high standard originates not only from bright and innovative people but also from the ability to work together, share knowledge and ideas and make use of people´s different skills, all qualities possessed by this department. Thank you for having introduced me to epidemiological research, I have definitely been encouraged to continue research in this field. Also I would like to say thank you for giving me the possibility to go to Boston for three months during my research year. It has been an experience of great personal and intellectual gain. A special thanks to Elizabeth Hatch who have warmly welcomed us at the Department of Public Health, Boston University.
    [Show full text]
  • Medical Guidelines Important Medical Precautions
    Safety at the Ceremonies & Medical Guidelines Important Medical Precautions Ricardo has many years of experience in holding medicine events and knows the safe use of Ayahuasca in its traditional context. Please note that in certain cases working with Ayahuasca can carry health risks: if you have any heart, liver or kidney, or other serious medical problems, you should inform us at the first opportunity, and discuss the issues with a doctor who is aware of the issues Ayahuasca may raise. Our priority is your safety and well-being, within the events guiding you to personal healing and growth. We will provide the most secure environment to work with Ayahuasca we possibly can, and will ensure your welfare as best we can at all time. In return we ask that you behave responsibly and do not endanger yourself or others. It is necessary that you agree to disclose, in confidence, any known medical conditions and/or use of any medication, at the time of booking. By coming to the medicine event, you are declaring that you are in a physical and mental condition appropriate to the activities described in the dietary and medical guidelines, and agree that you participate at your own risk and that we cannot accept liability for any accident or injury. Certain drugs and medications have been found to not be compatible with Ayahuasca. It is essential to stop taking the following substances, and give your system sufficient time to remove them from the body, before you begin a workshop. Please consult your doctor if you are in any doubt: you certainly should not suddenly stop taking prescribed medications (including antidepressants) without consulting your doctor.
    [Show full text]
  • Synthesis of Enantioenriched Piperidine-Based, Spirocyclic Analogues of AF64A and Acetylcholine
    Loyola University Chicago Loyola eCommons Dissertations Theses and Dissertations 1994 Synthesis of Enantioenriched Piperidine-Based, Spirocyclic Analogues of AF64A and Acetylcholine Nam Huh Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_diss Part of the Chemistry Commons Recommended Citation Huh, Nam, "Synthesis of Enantioenriched Piperidine-Based, Spirocyclic Analogues of AF64A and Acetylcholine" (1994). Dissertations. 3465. https://ecommons.luc.edu/luc_diss/3465 This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. Copyright © 1994 Nam Huh LOYOLA UNIVERSITY OF CIDCAGO SYNTHESIS OF ENANTIOENRICHED PIPERIDINE-BASED, SPIROCYCLIC ANALOGUES OF AF64A AND ACETYLCHOLINE A DISSERTATION SUBMITI'ED TO THE FACULTY OF THE GRADUATE SCHOOL IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF CHEMISTRY BY NAM HUH CHICAGO, IL MAY 1994 Copyright by Nam Huh, 1994 All rights reserved 11 ACKNOWLEDGEMENT The author wishes to express his deepest gratitude to Dr. Charles M. Thompson for his persistent motivation, his continual support, and his friendship; all of which made this work possible. Thanks are expressed to the members of the Dissertation Committee: Dr. Leslie W. M. Fung, Dr. David S. Crumrine, and Prof. Israel Hanin, for their willingness to serve in this capacity. The author would also like to thank all of the Organic Division students, especially those in the "Thompson Group", who made life on the second floor endurable.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Alaproclate (hydrochloride) Item No. 27770 CAS Registry No.: 60719-83-7 Formal Name: alanine, 2-(4-chlorophenyl)-1,1- dimethylethyl ester, monohydrochloride NH Synonyms: GEA 654, A03 2 MF: C13H18ClNO2 • HCl O FW: 292.2 Purity: ≥95% O UV/Vis.: λmax: 222 nm Cl • HCl Supplied as: A crystalline solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Alaproclate (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the alaproclate (hydrochloride) in water. We do not recommend storing the aqueous solution for more than one day. Description Alaproclate is a selective serotonin reuptake inhibitor (SSRI).1,2 It inhibits depletion of serotonin (5-HT) induced by 4-methyl-α-ethyl-m-tyramine in rat cerebral cortex, hippocampus, hypothalamus, 1 and striatum (EC50s = 18, 4, 8, and 12 mg/kg, respectively). Alaproclate inhibits NMDA-evoked currents and depolarization-induced voltage-dependent potassium currents in rat hippocampal neurons (IC50s = 1.1 and 6.9 μM, respectively) and does not inhibit GABA-evoked currents when used at concentrations up to 100 μM.2 It increases sirtuin 1 (SIRT1) levels in N2a murine neuroblastoma cells expressing apolipoprotein E4 (ApoE4; IC50 = 2.3 μM) and in the hippocampus in the FXFAD-ApoE4 transgenic mouse model of Alzheimer’s disease when administered at a dose of 20 mg/kg twice daily.3 Alaproclate (40 mg/kg) decreases immobility time in the forced swim test in rats, indicating antidepressant- like activity.4 References 1.
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]
  • Basic and Clinical Aspects of Depression
    Abstracts of Poster Presentations 259 31.01.01 PHARMACOTHERAPY, PSYCHOTHERAPY, AND PSYCHOEDUCATIONAL INTERVENTIONS: EFFICACY IN RECURRENT DEPRESSION POSTER E. Frank, and D. J. Kupfer We are currently engaged in a study of maintenance treatments for PRESENTATION recurrent unipolar depression which compares the efficacy of psychotherapy, pharmacotherapy and their combination. Rather 31.01 than focusing exclusively on the number of recurrences in each of the experimental conditions, we have also been concerned with the quality of patients' lives between episodes and with the !ength of the symptom-free interval. The three-year maintenance phase of our study is still in progress; therefore, final results will not be available for another 18 months to 2 years. We can, however, discuss the information available on Basic and Clinical Aspects those 62 patients who have already experienced a recurrence of illness and for whom the blind has been broken. While the majority of Depression of recurrences have been experienced by patients in the non- medication conditions, it would appear that, with or without medication, psychotherapy has had a significant effect in delaying the onset of a new episode. At this point in time, however, we have little evidence that continued psychotherapy adds to the generally good quality of patients' social functioning in symptom-free interval. A full understanding of the additive and interactive effects of pharmacotherapy and psychotherapy in the treatment of recurrent depression must await the completion of this study
    [Show full text]
  • Antidepressant Treatment for Postnatal Depression
    This is a repository copy of Antidepressant treatment for postnatal depression. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/163986/ Version: Published Version Article: Brown, Jennifer Valeska Elli orcid.org/0000-0003-0943-5177, Wilson, Claire A., Ayre, Karyn et al. (5 more authors) (2020) Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews. CD013560. ISSN 1469-493X https://doi.org/10.1002/14651858.CD013560 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Library Cochrane Database of Systematic Reviews Antidepressant treatment for postnatal depression (Protocol) Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H. Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No.: CD013560. DOI: 10.1002/14651858.CD013560. www.cochranelibrary.com Antidepressant treatment for postnatal depression (Protocol) Copyright © 2020 The Cochrane Collaboration.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/20 (2006.01) A61K 31/485 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/EP2013/06385 1 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, 1 July 20 13 (01 .07.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PA 2012 70405 6 July 2012 (06.07.2012) DK (84) Designated States (unless otherwise indicated, for every 61/668,741 6 July 2012 (06.07.2012) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: EGALET LTD.
    [Show full text]